Efficacy and safety of two doses of S 90098 [agomelatine] (1 and 2 mg/day), sublingual formulation for 8 weeks in out-patients with major depressive disorder: An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks.

Trial Profile

Efficacy and safety of two doses of S 90098 [agomelatine] (1 and 2 mg/day), sublingual formulation for 8 weeks in out-patients with major depressive disorder: An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks.

Suspended
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2013

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms FIGARO
  • Sponsors IRIS
  • Most Recent Events

    • 15 Mar 2012 This trial has been completed in Finland, Czech Republic, Estonia, Lithuania and recruiting in France.
    • 23 Jul 2009 Additional location (England) identified as reported by United Kingdom Clinical Research Network.
    • 23 Jul 2009 New source identified and integrated (United Kingdom Clinical Research Network).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top